Stem cell injection or knee replacement: what to check first

What to try before an operation

Start with movement that doesn't cause a sharp rise in soreness. Physical therapy can help you choose safe exercises.

Too much rest can leave the joint weaker. Gentle exercise works like easing a stiff hinge.

What to learn from the X-ray

Ask your doctor to show the worn spot on your X-ray. Have the doctor match that spot with where you hurt.

An X-ray that looks bad doesn't always mean severe soreness. Also weigh your strength, sleep, range of motion, and daily chores.

Use the exam and X-ray together when discussing surgery. A single visit won't settle all your questions about an operation.

When to ask a surgeon about replacement

Ask for a surgeon's opinion when basic daily tasks become hard. Also ask when you ache while resting, the joint changes shape, or it barely moves.

A surgeon can explain the recovery and risks that apply to you. That meeting doesn't put an operation on the calendar.

Waiting may fit while walking and sleep stay steady. Speak up when each month takes away another task.

What to do if it doesn't settle

Before surgery, QC Kinetix can discuss regenerative treatments, clinic procedures prepared from material in your body. Staff who examine the joint and give care are called medical providers.

Ask how an option compares with therapy and a surgeon's advice. No clinic can promise how long relief will last.

You'll need to compare cost, recovery, later visits, and daily limits. Your doctor can help you weigh them.

Sources

1. A systematic review of 21 studies re-examining the familiar '20 percent are dissatisfied after knee replacement' figure found the actual average dissatisfaction rate was 10 percent, and 7.3 percent when complications were excluded - the surgical benchmark a cash-pay injection is implicitly competing against.

   DeFrance MJ, et al. — Are 20% of Patients Actually Dissatisfied Following Total Knee Arthroplasty? A Systematic Review of the Literature. J Arthroplasty, 2023. DOI: 10.1016/j.arth.2022.10.011.

2. The AAOS Surgical Management of Osteoarthritis of the Knee clinical practice guideline sets out 16 recommendations and seven options for surgical management based on a systematic review of the published evidence - the reference point for when a joint has moved past the injectable tier.

   Srivastava AK, et al. — American Academy of Orthopaedic Surgeons Clinical Practice Guideline Summary of Surgical Management of Osteoarthritis of the Knee. J Am Acad Orthop Surg, 2023. DOI: 10.5435/JAAOS-D-23-00338.

3. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

4. A double-blind randomized trial testing whether adding bone marrow aspirate concentrate to arthroscopic partial meniscectomy improves outcomes in patients with early knee osteoarthritis used the IKDC score at one year as its primary endpoint, with Kellgren-Lawrence grade as a radiographic secondary.

   Yanke AB, et al. — A Prospective, Randomized, Double-Blind Clinical Trial to Investigate the Efficacy of Autologous Bone Marrow Aspirate Concentrate During Arthroscopic Meniscectomy in Patients With Early Knee Osteoarthritis. Am J Sports Med, 2024. DOI: 10.1177/03635465241275647.

5. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

6. MACI is FDA-licensed (STN BL 125603, Vericel Corporation) and is indicated for the repair of symptomatic, single or multiple FULL-THICKNESS cartilage defects of the knee with or without bone involvement in adults - a focal defect repair performed surgically, not a treatment for osteoarthritis and not an injection.

   US Food and Drug Administration — MACI (autologous cultured chondrocytes on porcine collagen membrane). , 2016.